Skip to content

Photodynamic therapy drug monitoring of port-wine CM: construction and application of a highly sensitive SERS microneedle sensor

Photodynamic therapy drug monitoring of port-wine CM for personalized treatment: construction and application of a highly sensitive SERS microneedle sensor

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114544
Enrollment
Unknown
Registered
2025-12-15
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Port wine CM

Interventions

Observation group 1 (8-18 years):None
Observation group 2(19-60 years):None
Observation group 3(2-7 years):None

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 2-60 years old (including upper and lower limits); 2. Clear diagnosis of port-wine stain; 3. It can include isolated PWS and related syndromes such as Sturge-Weber syndrome (SWS), phakomatosis pigmentovascularis (PPV), etc. The erythema should be relatively isolated from the other lesions of the syndrome, that is, there are no other related skin pathological changes at the site of the erythema, such as dermal melanocytosis. 4.The interval between photodynamic therapy and the last erythema treatment was at least 3 months; 5. After fully understanding the protocol and risks, I or my guardian will sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1. Infection, eczema, ulcer, or other pigmented diseases such as nevus of Ota at the lesion site; 2. History of seizures or uncontrolled seizures in the past six months; 3. Allergy to porphyrins or allergic constitution; 4. Scar constitution; 5. A history of sun exposure in the past 3 months; 6. There are potential diseases such as abnormal electrocardiogram, organic heart disease, abnormal liver function, pregnancy or pregnant women that may affect treatment; 7. Refuse blood collection or fail to cooperate with the blood collection process; 8. Recent use (within 1 month) of drugs that affect the study drug metabolism, or combined with serious underlying diseases that may interfere with drug metabolism (such as inherited metabolic diseases); 9. Persons participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Drug concentration;

Countries

China

Contacts

Public ContactMa Gang

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

docmagang@126.com+86 21 23271699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026